Acuitas Is a Great Place to Work! (Why You Should Work Here!)
Finding a great place to work which is purpose driven is a goal for many, and we completely understand (and endorse!) that. Good work/life integration is an important aspect of our professional lives – and so is working with a
Our Unique Business Model
The Acuitas business model is unique. As the global leader in developing lipid nanoparticles (LNP) for nucleic acid therapeutics, our full focus is on refining and improving our LNP for use by our partners. Supporting partner success is at the heart
Acuitas – Who We Are and How We Got Here
As the global leader in developing lipid nanoparticles (LNP) for nucleic acid therapeutics, the Acuitas team advances human health through our work with our partners – and by continuing to refine and improve our LNP. We are growing our team and
Acuitas Therapeutics Video Update
Acuitas Therapeutics is the global leader in the field of lipid nanotechnology. We specialize in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP). We work with partners to develop new therapies to address unmet
Long COVID – What You Need to Know
As many countries (including Canada) shift into a post-pandemic environment, there are still important aspects to be aware of. The first is that there is still a risk of contracting COVID-19. People who are fully vaccinated can still get COVID-19.
Why I Work at Acuitas – A Project Manager’s Perspective
Today’s installment in our "Why I Work at Acuitas" series is with Acuitas’ Sr. Associate, Project Manager, Dr. Baishakhi Datta. We recently caught up with Dr. Datta and asked her a few questions about why she chose to work at
Acuitas Therapeutics Video Update
Acuitas Therapeutics is a global leader in the field of lipid nanotechnology. The team, led by President & CEO, Dr. Thomas Madden, is made up of a diverse group of highly experienced scientists and technical and administrative professionals – all
COVID-19 Vaccines and Children – an Important Conversation
Health Canada has approved the Pfizer/BioNTech COMIRNATY® mRNA vaccine for children ages five to 11. (This vaccine uses Acuitas Therapeutics’ lipid nanoparticle delivery system.) All vaccines approved for use in Canada undergo a strict testing, review and approval process. The Government
New Acuitas Therapeutics Video
Acuitas Therapeutics partners with pharmaceutical companies, biotechnology companies and academic institutes to advance nucleic acid therapeutics to the clinic and to the marketplace. After more than a decade of work on our lipid nanoparticle delivery system, it now plays a
What You Need to Know About COVID-19 Vaccines for Children
The Pfizer/BioNTech COVID-19 vaccine COMIRNATY® has received Health Canada’s approval for children ages five to 11. (Acuitas provides the lipid nanoparticle delivery system for this mRNA vaccine.) In a CBC article, which is in a useful Q&A format, a spokesperson for